Healthcare Global Enterprises Limited — Investor Meet, 26-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

HCG saw Q4 FY26 revenue hit INR 652 Cr (+11.3% YoY) and full-year revenue INR 2,545 Cr (+15% YoY). Adjusted EBITDA margins improved to 19.2% (Q4) and 18.5% (FY26). Net debt to EBITDA reduced to 1.4x. The company launched its North Bangalore facility with MR-Linac and divested its non-core Milann fertility business for INR 63 Cr enterprise value, sharpening oncology focus. Management aims for ~15% medium-term growth via network optimization, adding 200 brownfield beds (Cuttack, Ranchi, Vizag, Bhavnagar), and talent acquisition. HCG targets profitable expansion and sustained margin improvement, reflecting a confident outlook.